請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/83297
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 魏子堂 | zh_TW |
dc.contributor.advisor | Tzu-Tang Wei | en |
dc.contributor.author | 洪佐宜 | zh_TW |
dc.contributor.author | Zuo-Yi Hong | en |
dc.date.accessioned | 2023-03-02T17:02:19Z | - |
dc.date.available | 2023-11-10 | - |
dc.date.copyright | 2023-05-24 | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2023-02-17 | - |
dc.identifier.citation | King, T.E., Jr., A. Pardo, and M. Selman, Idiopathic pulmonary fibrosis. Lancet, 2011. 378(9807): p. 1949-61.
Martinez, F.J., et al., Idiopathic pulmonary fibrosis. Nat Rev Dis Primers, 2017. 3: p. 17074. Richeldi, L., H.R. Collard, and M.G. Jones, Idiopathic pulmonary fibrosis. Lancet, 2017. 389(10082): p. 1941-1952. Raghu, G., et al., An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med, 2011. 183(6): p. 788-824. Hutchinson, J., et al., Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J, 2015. 46(3): p. 795-806. Ley, B., H.R. Collard, and T.E. King, Jr., Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2011. 183(4): p. 431-40. Hewson, T., et al., Timing of onset of symptoms in people with idiopathic pulmonary fibrosis. Thorax, 2017. Bodempudi, V., et al., miR-210 promotes IPF fibroblast proliferation in response to hypoxia. Am J Physiol Lung Cell Mol Physiol, 2014. 307(4): p. L283-94. Harari, S. and A. Caminati, IPF: new insight on pathogenesis and treatment. Allergy, 2010. 65(5): p. 537-53. Stanton, G.J., et al., Interferon review. Invest Radiol, 1987. 22(3): p. 259-73. Lee, A.J. and A.A. Ashkar, The Dual Nature of Type I and Type II Interferons. Front Immunol, 2018. 9: p. 2061. Platanias, L.C., Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol, 2005. 5(5): p. 375-86. Varone, F., et al., Nintedanib for the treatment of idiopathic pulmonary fibrosis. Expert Opin Pharmacother, 2018. 19(2): p. 167-175. Azuma, A., et al., Interferon-beta inhibits bleomycin-induced lung fibrosis by decreasing transforming growth factor-beta and thrombospondin. Am J Respir Cell Mol Biol, 2005. 32(2): p. 93-8. Vu, T.N., et al., Interferon-gamma enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation. Respir Res, 2019. 20(1): p. 206. Smaldone, G.C., Repurposing of gamma interferon via inhalation delivery. Adv Drug Deliv Rev, 2018. 133: p. 87-92. Fusiak, T., G.C. Smaldone, and R. Condos, Pulmonary Fibrosis Treated with Inhaled Interferon-gamma (IFN-gamma). J Aerosol Med Pulm Drug Deliv, 2015. 28(5): p. 406-10. Skaria, S.D., et al., Inhaled Interferon and Diffusion Capacity in Idiopathic Pulmonary Fibrosis (IPF). Sarcoidosis Vasc Diffuse Lung Dis, 2015. 32(1): p. 37-42. Bodier-Montagutelli, E., et al., Designing inhaled protein therapeutics for topical lung delivery: what are the next steps? Expert Opin Drug Deliv, 2018. 15(8): p. 729-736. Liang, W., et al., Pulmonary Delivery of Biological Drugs. Pharmaceutics, 2020. 12(11). Maselli, D.J., H. Keyt, and M.I. Restrepo, Inhaled Antibiotic Therapy in Chronic Respiratory Diseases. Int J Mol Sci, 2017. 18(5). Respaud, R., et al., Effect of formulation on the stability and aerosol performance of a nebulized antibody. MAbs, 2014. 6(5): p. 1347-55. Ari, A., Jet, ultrasonic, and mesh nebulizers: an evaluation of nebulizers for better clinical outcomes. 2014. Flament, M.P., P. Leterme, and A. Gayot, Study of the technological parameters of ultrasonic nebulization. Drug Dev Ind Pharm, 2001. 27(7): p. 643-9. Dennis, J.H., A review of issues relating to nebulizer standards. J Aerosol Med, 1998. 11 Suppl 1: p. S73-9. Pritchard, J.N., et al., Mesh nebulizers have become the first choice for new nebulized pharmaceutical drug developments. Ther Deliv, 2018. 9(2): p. 121-136. Waldrep, J.C. and R. Dhand, Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation. Curr Drug Deliv, 2008. 5(2): p. 114-9. Hertel, S., et al., That's cool!--Nebulization of thermolabile proteins with a cooled vibrating mesh nebulizer. Eur J Pharm Biopharm, 2014. 87(2): p. 357-65. Hertel, S.P., G. Winter, and W. Friess, Protein stability in pulmonary drug delivery via nebulization. Advanced drug delivery reviews, 2015. 93: p. 79-94. Frohlich, E. and S. Salar-Behzadi, Oral inhalation for delivery of proteins and peptides to the lungs. Eur J Pharm Biopharm, 2021. 163: p. 198-211. Morales, J.O., et al., Challenges and Future Prospects for the Delivery of Biologics: Oral Mucosal, Pulmonary, and Transdermal Routes. AAPS J, 2017. 19(3): p. 652-668. Ewert, R., et al., Inhaled iloprost for therapy in pulmonary arterial hypertension. Expert Rev Respir Med, 2011. 5(2): p. 145-52. Shirley, M., Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease. Drugs, 2019. 79(5): p. 555-562. Pham, S., et al., In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution. J Aerosol Med Pulm Drug Deliv, 2018. 31(3): p. 162-169. Beck-Broichsitter, M., et al., Impact of lyoprotectants for the stabilization of biodegradable nanoparticles on the performance of air-jet, ultrasonic, and vibrating-mesh nebulizers. Eur J Pharm Biopharm, 2012. 82(2): p. 272-80. Hsu, H.S., et al., Involvement of ER stress, PI3K/AKT activation, and lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis. Sci Rep, 2017. 7(1): p. 14272. Lu, Y., et al., Phosphatidylinositol-3-kinase/akt regulates bleomycin-induced fibroblast proliferation and collagen production. Am J Respir Cell Mol Biol, 2010. 42(4): p. 432-41. Zhao, H., et al., Baicalin alleviates bleomycin‑induced pulmonary fibrosis and fibroblast proliferation in rats via the PI3K/AKT signaling pathway. Mol Med Rep, 2020. 21(6): p. 2321-2334. Buchwalder, P.A., et al., Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res, 2000. 20(10): p. 857-66. Fernandez, I.E. and O. Eickelberg, The impact of TGF-beta on lung fibrosis: from targeting to biomarkers. Proc Am Thorac Soc, 2012. 9(3): p. 111-6. Holm Nielsen, S., et al., Serological Assessment of Activated Fibroblasts by alpha-Smooth Muscle Actin (alpha-SMA): A Noninvasive Biomarker of Activated Fibroblasts in Lung Disorders. Transl Oncol, 2019. 12(2): p. 368-374. Breton, J.D., et al., Molecular changes during TGFbeta-mediated lung fibroblast-myofibroblast differentiation: implication for glucocorticoid resistance. Physiol Rep, 2018. 6(7): p. e13669. Battaglia, R.A., et al., Vimentin on the move: new developments in cell migration. F1000Res, 2018. 7. Walter, M.R., The Role of Structure in the Biology of Interferon Signaling. Front Immunol, 2020. 11: p. 606489. Lauren, S.L., et al., Covalent dimerization of recombinant human interferon-gamma. Arch Biochem Biophys, 1993. 306(2): p. 350-3. Lunn, C.A., et al., An active covalently linked dimer of human interferon-gamma. Subunit orientation in the native protein. J Biol Chem, 1992. 267(25): p. 17920-4. Matute-Bello, G., C.W. Frevert, and T.R. Martin, Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol, 2008. 295(3): p. L379-99. Jules-Elysee, K. and D.A. White, Bleomycin-induced pulmonary toxicity. Clin Chest Med, 1990. 11(1): p. 1-20. Della Latta, V., et al., Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions. Pharmacol Res, 2015. 97: p. 122-30. Liu, Y., et al., Methods for quantifying fibrillar collagen alignment, in Fibrosis. 2017, Springer. p. 429-451. Moseley, P.L., C. Hemken, and G.W. Hunninghake, Augmentation of fibroblast proliferation by bleomycin. J Clin Invest, 1986. 78(5): p. 1150-4. Sampson, U.K., et al., Global and regional burden of aortic dissection and aneurysms: mortality trends in 21 world regions, 1990 to 2010. Glob Heart, 2014. 9(1): p. 171-180 e10. Sidloff, D., et al., Mortality from thoracic aortic diseases and associations with cardiovascular risk factors. Circulation, 2014. 130(25): p. 2287-94. Faluk, M. and O. De Jesus, Saccular Aneurysm, in StatPearls. 2022: Treasure Island (FL). Genoni, M., et al., Chronic beta-blocker therapy improves outcome and reduces treatment costs in chronic type B aortic dissection. Eur J Cardiothorac Surg, 2001. 19(5): p. 606-10. Tchana-Sato, V., N. Sakalihasan, and J.O. Defraigne, [Aortic dissection]. Rev Med Liege, 2018. 73(5-6): p. 290-295. Sayed, A., M. Munir, and E.I. Bahbah, Aortic Dissection: A Review of the Pathophysiology, Management and Prospective Advances. Curr Cardiol Rev, 2021. 17(4): p. e230421186875. Sievers, H.H., et al., Aortic dissection reconsidered: type, entry site, malperfusion classification adding clarity and enabling outcome prediction. Interact Cardiovasc Thorac Surg, 2020. 30(3): p. 451-457. Gawinecka, J., F. Schonrath, and A. von Eckardstein, Acute aortic dissection: pathogenesis, risk factors and diagnosis. Swiss Med Wkly, 2017. 147: p. w14489. Harky, A., et al., The Aortic Pathologies: How Far We Understand It and Its Implications on Thoracic Aortic Surgery. Braz J Cardiovasc Surg, 2021. 36(4): p. 535-549. Milleron, O., et al., Pathogenic FBN1 Genetic Variation and Aortic Dissection in Patients With Marfan Syndrome. J Am Coll Cardiol, 2020. 75(8): p. 843-853. Pratt, B. and J. Curci, Arterial elastic fiber structure. Function and potential roles in acute aortic dissection. J Cardiovasc Surg (Torino), 2010. 51(5): p. 647-56. Isselbacher, E.M., C.L. Lino Cardenas, and M.E. Lindsay, Hereditary Influence in Thoracic Aortic Aneurysm and Dissection. Circulation, 2016. 133(24): p. 2516-28. Wong, D.R., S.A. Lemaire, and J.S. Coselli, Managing dissections of the thoracic aorta. Am Surg, 2008. 74(5): p. 364-80. Luo, W., et al., Critical Role of Cytosolic DNA and Its Sensing Adaptor STING in Aortic Degeneration, Dissection, and Rupture. Circulation, 2020. 141(1): p. 42-66. Elefteriades, J.A. and E.A. Farkas, Thoracic aortic aneurysm clinically pertinent controversies and uncertainties. J Am Coll Cardiol, 2010. 55(9): p. 841-57. Chun, A.S., J.A. Elefteriades, and S.K. Mukherjee, Medical treatment for thoracic aortic aneurysm - much more work to be done. Prog Cardiovasc Dis, 2013. 56(1): p. 103-8. Milewicz, D.M. and F. Ramirez, Therapies for Thoracic Aortic Aneurysms and Acute Aortic Dissections. Arterioscler Thromb Vasc Biol, 2019. 39(2): p. 126-136. Ouzounian, M., et al., Open repair of thoracoabdominal aortic aneurysm: step-by-step. Operative Techniques in Thoracic and Cardiovascular Surgery, 2018. 23(1): p. 2-20. Harky, A., et al., Current challenges in open versus endovascular repair of ruptured thoracic aortic aneurysm. J Vasc Surg, 2018. 68(5): p. 1582-1592. Saeyeldin, A.A., et al., Thoracic aortic aneurysm: unlocking the "silent killer" secrets. Gen Thorac Cardiovasc Surg, 2019. 67(1): p. 1-11. Takahashi, K. and S. Yamanaka, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006. 126(4): p. 663-76. Zheng, Y.L., Some Ethical Concerns About Human Induced Pluripotent Stem Cells. Sci Eng Ethics, 2016. 22(5): p. 1277-1284. Hockemeyer, D. and R. Jaenisch, Induced Pluripotent Stem Cells Meet Genome Editing. Cell Stem Cell, 2016. 18(5): p. 573-86. Zhao, M., et al., Mesenchymal Stem Cell-Derived Extracellular Vesicles Attenuate Mitochondrial Damage and Inflammation by Stabilizing Mitochondrial DNA. ACS Nano, 2021. 15(1): p. 1519-1538. Weng, Z., et al., Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer. J Hematol Oncol, 2021. 14(1): p. 136. Keshtkar, S., N. Azarpira, and M.H. Ghahremani, Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine. Stem Cell Res Ther, 2018. 9(1): p. 63. Harrell, C.R., et al., Mesenchymal Stem Cell-Derived Exosomes and Other Extracellular Vesicles as New Remedies in the Therapy of Inflammatory Diseases. Cells, 2019. 8(12). Wu, P., et al., MSC-exosome: A novel cell-free therapy for cutaneous regeneration. Cytotherapy, 2018. 20(3): p. 291-301. Toh, W.S., et al., MSC exosome as a cell-free MSC therapy for cartilage regeneration: Implications for osteoarthritis treatment. Semin Cell Dev Biol, 2017. 67: p. 56-64. Phinney, D.G. and M.F. Pittenger, Concise Review: MSC-Derived Exosomes for Cell-Free Therapy. Stem Cells, 2017. 35(4): p. 851-858. van Niel, G., G. D'Angelo, and G. Raposo, Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol, 2018. 19(4): p. 213-228. Abels, E.R. and X.O. Breakefield, Introduction to Extracellular Vesicles: Biogenesis, RNA Cargo Selection, Content, Release, and Uptake. Cell Mol Neurobiol, 2016. 36(3): p. 301-12. Zaborowski, M.P., et al., Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study. Bioscience, 2015. 65(8): p. 783-797. Sun, I.O., et al., Circulating miRNAs in extracellular vesicles related to treatment response in patients with idiopathic membranous nephropathy. J Transl Med, 2022. 20(1): p. 224. Spinelli, C., et al., Extracellular Vesicles as Conduits of Non-Coding RNA Emission and Intercellular Transfer in Brain Tumors. Noncoding RNA, 2018. 5(1). Jung, J.H., X. Fu, and P.C. Yang, Exosomes Generated From iPSC-Derivatives: New Direction for Stem Cell Therapy in Human Heart Diseases. Circ Res, 2017. 120(2): p. 407-417. Xia, Y., et al., Small extracellular vesicles secreted by human iPSC-derived MSC enhance angiogenesis through inhibiting STAT3-dependent autophagy in ischemic stroke. Stem Cell Res Ther, 2020. 11(1): p. 313. Upadhya, R., et al., Extracellular vesicles from human iPSC-derived neural stem cells: miRNA and protein signatures, and anti-inflammatory and neurogenic properties. J Extracell Vesicles, 2020. 9(1): p. 1809064. Gao, L., et al., Exosomes secreted by hiPSC-derived cardiac cells improve recovery from myocardial infarction in swine. Sci Transl Med, 2020. 12(561). Guo, X., et al., Induced pluripotent stem cell-conditional medium inhibits H9C2 cardiomyocytes apoptosis via autophagy flux and Wnt/beta-catenin pathway. J Cell Mol Med, 2019. 23(6): p. 4358-4374. Guo, X., et al., Induced pluripotent stem cell-derived conditional medium promotes Leydig cell anti-apoptosis and proliferation via autophagy and Wnt/beta-catenin pathway. J Cell Mol Med, 2018. 22(7): p. 3614-3626. Chang, H.M., et al., Using induced pluripotent stem cell-derived conditional medium to attenuate the light-induced photodamaged retina of rats. J Chin Med Assoc, 2015. 78(3): p. 169-76. Braverman, A.C., et al., Clinical Features and Outcomes of Pregnancy-Related Acute Aortic Dissection. JAMA Cardiol, 2021. 6(1): p. 58-66. Sawada, H., et al., beta-Aminopropionitrile-induced aortic aneurysm and dissection in mice. JVS Vasc Sci, 2022. 3: p. 64-72. Park, J.B., et al., The increased expression of matrix metalloproteinases associated with elastin degradation and fibrosis of the ligamentum flavum in patients with lumbar spinal stenosis. Clin Orthop Surg, 2009. 1(2): p. 81-9. Sugimoto, K., et al., Matrix metalloproteinase promotes elastic fiber degradation in ligamentum flavum degeneration. PLoS One, 2018. 13(8): p. e0200872. Kyrylkova, K., et al., Detection of apoptosis by TUNEL assay. Methods Mol Biol, 2012. 887: p. 41-7. Suchorska, W.M. and M.S. Lach, The role of exosomes in tumor progression and metastasis (Review). Oncol Rep, 2016. 35(3): p. 1237-44. Jia, L.X., et al., ER stress dependent microparticles derived from smooth muscle cells promote endothelial dysfunction during thoracic aortic aneurysm and dissection. Clin Sci (Lond), 2017. 131(12): p. 1287-1299. Chen, Y., et al., Targeting regulated cell death in aortic aneurysm and dissection therapy. Pharmacol Res, 2022. 176: p. 106048. Chakraborty, A., et al., Programmed cell death in aortic aneurysm and dissection: A potential therapeutic target. J Mol Cell Cardiol, 2022. 163: p. 67-80. Ren, W., et al., beta-Aminopropionitrile monofumarate induces thoracic aortic dissection in C57BL/6 mice. Sci Rep, 2016. 6: p. 28149. Jia, L.X., et al., Mechanical stretch-induced endoplasmic reticulum stress, apoptosis and inflammation contribute to thoracic aortic aneurysm and dissection. J Pathol, 2015. 236(3): p. 373-83. Tang, H.Y., et al., Vascular Smooth Muscle Cells Phenotypic Switching in Cardiovascular Diseases. Cells, 2022. 11(24). Zhang, F., et al., An update on the phenotypic switching of vascular smooth muscle cells in the pathogenesis of atherosclerosis. Cell Mol Life Sci, 2021. 79(1): p. 6. Petsophonsakul, P., et al., Role of Vascular Smooth Muscle Cell Phenotypic Switching and Calcification in Aortic Aneurysm Formation. Arterioscler Thromb Vasc Biol, 2019. 39(7): p. 1351-1368. Mao, N., et al., Phenotypic switching of vascular smooth muscle cells in animal model of rat thoracic aortic aneurysm. Interact Cardiovasc Thorac Surg, 2015. 21(1): p. 62-70. Zhang, Y.N., et al., Phenotypic switching of vascular smooth muscle cells in the 'normal region' of aorta from atherosclerosis patients is regulated by miR-145. J Cell Mol Med, 2016. 20(6): p. 1049-61. Pahk, K., et al., Visualization of Synthetic Vascular Smooth Muscle Cells in Atherosclerotic Carotid Rat Arteries by F-18 FDG PET. Sci Rep, 2017. 7(1): p. 6989. Matsushita, T., et al., Relationship of connexin43 expression to phenotypic modulation in cultured human aortic smooth muscle cells. Eur J Cell Biol, 2007. 86(10): p. 617-28. Rabkin, S.W., Differential expression of MMP-2, MMP-9 and TIMP proteins in thoracic aortic aneurysm - comparison with and without bicuspid aortic valve: a meta-analysis. Vasa, 2014. 43(6): p. 433-42. Schips, T.G. and D. Vanhoutte, Marfan syndrome and aortic aneurysm: Lysyl oxidases to the rescue? J Mol Cell Cardiol, 2015. 86: p. 9-11. Takeda, N., et al., TGF-beta Signaling-Related Genes and Thoracic Aortic Aneurysms and Dissections. Int J Mol Sci, 2018. 19(7). Tingting, T., et al., The TGF-beta pathway plays a key role in aortic aneurysms. Clin Chim Acta, 2020. 501: p. 222-228. Daugherty, A., et al., Transforming Growth Factor-beta in Thoracic Aortic Aneurysms: Good, Bad, or Irrelevant? J Am Heart Assoc, 2017. 6(1). Holm, T.M., et al., Noncanonical TGFbeta signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science, 2011. 332(6027): p. 358-61. Chen, S.W., et al., Association of Long-term Use of Antihypertensive Medications With Late Outcomes Among Patients With Aortic Dissection. JAMA Netw Open, 2021. 4(3): p. e210469. Habashi, J.P., et al., Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science, 2011. 332(6027): p. 361-5. Kristensen, K.E., et al., Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with abdominal aortic aneurysms: nation-wide cohort study. Arterioscler Thromb Vasc Biol, 2015. 35(3): p. 733-40. | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/83297 | - |
dc.description.abstract | 第一部分:
特發性肺纖維化 (idiopathic pulmonary fibrosis, IPF) 為十分嚴重的肺部疾病,其特徵是肺部組織會產生瘢痕並導致呼吸困難。至今,IPF患者的治療選擇有限且病患存活率低。β型干擾素 (IFN-β) 目前已獲得美國食品藥物管理局 (FDA) 批准,使用於復發型多發性硬化症之治療,而許多研究也發現IFN-β具有IPF治療潛力。然而,最近研究指出:臨床上所使用的IFN-β無法改善患者總體存活率,其中一個可能原因為IFN-β通過靜脈或皮下注射的方式投予,順利到達肺臟的IFN-β藥量有限。在目前的藥物輸送系統中,藥物透過霧化方式已證明對於呼吸系統疾病具有較好的療效。然而,噴射型噴霧器 (jet nebulizer) 和超聲波噴霧器 (ultrasonic nebulizer) 在霧化過程中可能會引起蛋白質結構產生變化進而影響蛋白質藥物(如IFN-β)的治療效果。相比之下,網孔型噴霧器 (mesh nebulizer) 可能較不影響到蛋白質藥物完整性及原本的生物學功能。 本研究顯示,於人類肺纖維母細胞 (human lung fibroblast, HLF) 增殖測定實驗中,不論是透過博來黴素 (bleomycin, BLM) 劑量反應或是轉化生長因子β (transforming growth factor-beta, TGF-β) 誘導的HLF細胞增殖反應,皆能藉由給予原型IFN-β和氣霧化IFN-β所逆轉。此外,使用網孔型噴霧器製出的氣霧化IFN-β也可顯著降低TGF-β處理所誘導的HLF細胞遷移及分化成肌纖維母細胞之能力。有趣的是,透過網孔型噴霧器製出的氣霧化IFN-β在TGF-β誘導的HLF細胞增殖反應中的抑制效果甚至更優於原型IFN-β。我們的研究揭示了IFN-β在使用網孔型噴霧器後治療IPF的潛力,並提升其治療功效。 第二部分: 主動脈瘤及剝離 (aortic aneurysm and dissection (AAD)) 是廣泛存在的心血管疾病,其嚴重性會導致病患隨時有危及生命的疑慮。然而,AAD在出現併發症前難以檢測和診斷這種危險、無聲的疾病,而且全球的AAD發生率仍然不斷攀升中。許多研究都在探討AAD和以下幾個因素的關聯性,並試圖找到防止這種疾病進展的策略,包括:彈性蛋白及膠原蛋白的結構降解、基質金屬蛋白酶 (matrix metalloproteinase, MMP) 的表現量、平滑肌細胞 (smooth muscle cell, SMC) 損失、細胞外基質斷裂 (extracellular matrix, ECM)、轉化生長因子β信號級聯放大 (TGF-β signaling cascade)。然而,現今臨床上大多只能透過特定藥物或手術治療,例如:給予β受體阻滯劑 (beta blocker)、血管張力素II型受體拮抗劑 (angiotensin II receptor blocker)、他汀類藥物 (statin) 或進行胸主動脈瘤開胸修補術 (open thoracic aneurysm repair)、血管腔內胸主動脈瘤修復手術 (thoracic endovascular aortic repair)。 誘導性多功能幹細胞 (induced pluripotent stem cells, iPSCs) 是一種能從體細胞表達特定胚胎轉錄因子的組合進而重新編程的多能幹細胞,而其最大的優勢為:以自體為來源,促使iPSCs作為細胞治療上擁有取之不盡、用之不竭的來源,並且也不會出現免疫排斥或是倫理問題等諸多疑慮。此外,研究也發現人類誘導性多功能幹細胞之條件培養液 (human induced pluripotent stem cell-derived conditioned medium (hiPSC-CM) 具有治療疾病及病症之潛力,而原因可能來自於iPSCs分泌的細胞外囊泡 (extracellular vesicles, EVs) 擁有某些特定的影響。本研究發現:hiPSC-CM經冷凍乾燥機凍乾後能保留大部分營養成分。我們進一步透過動物實驗指出:老鼠的主動脈瘤總體發生率以及彈性纖維 (elastic fiber) 損失在給予hiPSC-CM後皆有下降之趨勢,揭示了hiPSC-CM應用於AAD的治療潛力,為此棘手的疾病提供一項新穎的預防策略。 | zh_TW |
dc.description.abstract | Part One:
Idiopathic pulmonary fibrosis (IPF) is a severe lung disease that results in breathing difficulty characterized by lung scarring. Nowadays, patients with IPF have limited therapeutic options and unfortunately exhibit poor survival. Interferon-beta (IFN-β) has been approved by the US Food and Drug Administration (FDA) for the treatment of relapsing multiple sclerosis, while it has also been found to exhibit therapeutic potential in IPF. However, recent studies showed that the clinical use of IFN-β did not show an improvement in overall survival. The delivery of IFN-β through intravenous or subcutaneous injection may explain the possible reason that IFN-β is not successfully delivered to the lungs. Among present drug delivery systems, aerosolized medication has demonstrated the enhanced efficacy of drugs for the treatment of respiratory diseases. Nevertheless, the degradation of protein drugs caused by the jet and ultrasonic nebulizers may reduce the therapeutic effects of those drugs, such as IFN-β. In the contrast, neither the structural integrity nor the biological function of nebulized IFN-β was compromised by the nebulization process within the mesh nebulizer. In bleomycin (BLM) dose-response or transforming growth factor-beta (TGF-β)-induced lung fibroblast proliferation assays, we found both parenteral IFN-β and IFN-β nebulized with the mesh nebulizer could rescue these effects. On top of that, nebulized IFN-β obtained with the mesh nebulizer considerably reduced the capacity of the migration and myofibroblast differentiation ability of TGF-β-treated HLF cells, and intriguingly showed more potent rescue effects than parenteral IFN-β in TGF-β-induced lung fibroblast proliferation. Our investigations revealed the potential efficacy of IFN-β in the treatment of IPF with the mesh nebulizer, demonstrating the higher efficiency of IFN-β. Part Two: Aortic aneurysm and dissection (AAD) are severe cardiovascular diseases worldwide that can cause life-threatening bleeding. Unfortunately, this parlous and silent disease is notoriously arduous to diagnose before cardiac complications, and the number of cases has increased. Nowadays, a great deal of research has focused on the structural degradation of elastin and collagen, matrix metalloproteinase (MMP) expression, progressive smooth muscle cell (SMC) loss, extracellular matrix (ECM) fragmentation, and transforming growth factor-beta (TGF-β) signaling cascade to explore a novel strategy to prevent AAD progression. However, there are only two methods clinically: specific medications (e.g., beta blockers, angiotensin II receptor blockers, and statins) and surgeries (e.g., open thoracic aneurysm repair and thoracic endovascular aortic repair) against this disease. Induced pluripotent stem cells (iPSCs) are a type of pluripotent stem cell that can be reprogrammed by expressing a combination of embryonic transcription factors from a somatic cell. The greatest advantage of iPSCs is their autologous source, which leads to utilizing iPSCs as an inexhaustible source for cell therapies without immune rejection or ethical issues. Besides, some studies have shown that human induced pluripotent stem cell-derived conditioned medium (hiPSC-CM) possesses therapeutic potential against diseases and disorders, which could be attributed to the extracellular vesicles (EVs) derived from iPSCs. In this study, hiPSC-CM was lyophilized by a freeze-dryer to retain most nutrients. With a lower overall incidence of aortic aneurysms and less dilatation of ascending thoracic aortas accompanied by diminished loss of elastic fibers in vivo, our investigations revealed the potential efficacy of hiPSC-CM in the treatment of AAD, providing new insight into preventing the progression of this intractable disease. | en |
dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2023-03-02T17:02:19Z No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2023-03-02T17:02:19Z (GMT). No. of bitstreams: 0 | en |
dc.description.tableofcontents | 口試委員會審定書 i
謝辭 ii Contents iv Part One: Stability and Activity of Interferon Beta to Treat Idiopathic Pulmonary Fibrosis with Different Nebulizer Technologies 1 中文摘要 2 Abstract 3 List of Figures 5 List of Tables 6 Abbreviations 7 Chapter 1. Introduction 8 1.1 Idiopathic pulmonary fibrosis (IPF) 9 1.2 Interferon-beta (IFN-β) 10 1.3 Mesh nebulizer 11 1.4 The aim of this study 13 Chapter 2. Materials and Methods 15 2.1 Materials 16 2.2 Aerosol characterization 16 2.3 Assessment of temperature inside nebulizer reservoirs 17 2.4 Cell culture 18 2.5 Preparation of nebulized IFN-β 18 2.6 Cell proliferation assay 19 2.7 Transwell migration assay 19 2.8 Real-time polymerase chain reaction (RT-qPCR) 20 2.9 Western blot analysis 20 2.10 Statistical analysis 21 Chapter 3. Results 22 3.1 The mesh nebulizer had a better aerosol characterization performance than the other two nebulizers. 23 3.2 The nebulized IFN-β had the largest temperature changes during nebulization within the ultrasonic nebulizer. 24 3.3 Nebulized IFN-β from the mesh nebulizer had more therapeutic effects on the proliferation of human lung fibroblast cells, compared with parenteral IFN-β and nebulized IFN-β from the jet and ultrasonic nebulizers. 25 3.4 Nebulized IFN-β reduced the migration ability and differentiation to myofibroblasts of HLF cells. 27 3.5 Nebulized IFN-β remained intact only generated by the mesh nebulizer, thus maintaining its functionality. 28 Chapter 4. Discussion 29 4.1 The mesh nebulizers are better inhalation devices in the analysis of aerosol characterization. 30 4.2 Temperature increases were observed in the ultrasonic and mesh nebulizers. 31 4.3 A shift in the protein band to approximately 48 kDa was found after nebulization by the mesh nebulizer. 31 4.4 Non-nebulized IFN-β had a lower effect on reducing the cell viability of HLF cells, compared with IFN-β nebulized with the mesh nebulizer. 32 4.5 The limitation of this study 34 Chapter 5. Conclusion 35 Chapter 6. Authors’ contributions and Funding 37 Figures and Tables 39 Supplementary Tables 49 ---------------------------------------- (boundary line) ---------------------------------------- 51 Part Two: Exploring the Therapeutic Potential of Lyophilized Conditioned Medium Derived from Induced Pluripotent Stem Cell for Aortic Aneurysm and Dissection 52 中文摘要 53 Abstract 55 List of Figures 57 List of Tables 58 Abbreviations 59 Chapter 1. Introduction 61 1.1 Aortic aneurysm and dissection (AAD) 62 1.2 Induced pluripotent stem cells (iPSCs) 64 1.3 The aim of this study 65 Chapter 2. Materials and Methods 66 2.1 Materials 67 2.2 Cell culture and Collection of hiPSC-CM 68 2.3 Aortic aneurysm and dissection (AAD) mouse model 69 2.4 Histological examination 70 2.5 Preparation of lyophilized medium 70 2.6 Nanoparticle tracking analysis (NTA) 71 2.7 Transthoracic echocardiography 72 2.8 Verhoeff’s Van Gieson (EVG) stain 72 2.9 Immunofluorescence (IF) stain 73 2.10 Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay 74 2.11 Statistical analysis 75 Chapter 3. Results 76 3.1 The total number of extracellular vesicles (EVs) was higher in the group of lyophilized hiPSC-CM. 77 3.2 The thoracic and abdominal aortic aneurysms’ overall incidence was lower in the group of lyophilized hiPSC-CM. 77 3.3 A less dilatation of maximal ascending thoracic aortas was consistent with reduced loss of elastic fibers in the group of lyophilized hiPSC-CM. 78 3.4 The apoptotic cells and vascular smooth muscle cell (VSMC) phenotypic switching within the ascending thoracic aortas had no significant difference among the three groups. 79 Chapter 4. Discussion 81 4.1 There was no statistically significant difference in the survival rate of mice in the experiment group. 82 4.2 The invisible apoptotic cells and consistency of vascular smooth muscle cell markers were observed within the ascending thoracic aortas among the three groups. 82 4.3 TGF-β pathway plays a key role in aortic aneurysm and dissection. 83 4.4 The limitation of this study 84 Chapter 5. Conclusion 85 Figures and Tables 87 Supplementary Tables 99 References 101 | - |
dc.language.iso | en | - |
dc.title | 針對心肺相關疾病開發新穎治療策略 | zh_TW |
dc.title | Developing New Therapeutic Approaches for the Treatment of Cardiopulmonary Disease | en |
dc.title.alternative | Developing New Therapeutic Approaches for the Treatment of Cardiopulmonary Disease | - |
dc.type | Thesis | - |
dc.date.schoolyear | 111-1 | - |
dc.description.degree | 碩士 | - |
dc.contributor.oralexamcommittee | 陳青周;吳卓鍇;楊鎧鍵 | zh_TW |
dc.contributor.oralexamcommittee | Ching-Chow Chen;Cho-Kai Wu;Kai-Chien Yang | en |
dc.subject.keyword | 特發性肺纖維化,β型干擾素,網孔型噴霧器,人類肺纖維母細胞,主動脈瘤及剝離,誘導性多功能幹細胞,人類誘導性多功能幹細胞之條件培養液,細胞外囊泡,凍乾培養液, | zh_TW |
dc.subject.keyword | Idiopathic pulmonary fibrosis (IPF),Interferon-beta (IFN-β),Mesh nebulizer,Human lung fibroblast (HLF),Aortic aneurysm and dissection (AAD),Induced pluripotent stem cells (iPSCs),Human induced pluripotent stem cell-derived conditioned medium (hiPSC-CM),Extracellular vesicles (EVs),Lyophilized medium, | en |
dc.relation.page | 109 | - |
dc.identifier.doi | 10.6342/NTU202300589 | - |
dc.rights.note | 未授權 | - |
dc.date.accepted | 2023-02-17 | - |
dc.contributor.author-college | 醫學院 | - |
dc.contributor.author-dept | 藥理學研究所 | - |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-111-1.pdf 目前未授權公開取用 | 3.88 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。